Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands
Empagliflozin, when added to SoC, is a cost-effective treatment option for patients irrespective of LVEF in the Netherlands.
Authors
- Cornelis Boersma (ORCID: https://orcid.org/0000-0002-1190-2638)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Lisa A. de Jong (ORCID: https://orcid.org/0000-0001-8814-0670)
- Hans‐Peter Brunner‐La Rocca (ORCID: https://orcid.org/0000-0002-4356-8566)
- Maaike Weersma
- Bart Slob (ORCID: https://orcid.org/0009-0008-9125-0190)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Boehringer Ingelheim (Netherlands) (NL)
- Open University of the Netherlands (NL)
Publication Details
- Journal
- American Journal of Cardiovascular Drugs
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s40256-025-00749-6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00